# FDA Approves NorthStar Medical Systems' Heparin Sodium Injectable The FDA has approved NorthStar Medical Systems' abbreviated new drug application (ANDA 211005) for heparin sodium injection, expanding the competitive landscape in the anticoagulant market and potentially increasing pricing pressure among manufacturers of this widely-used blood thinner. The intravenous formulation approval allows NorthStar to capture additional market share in the hospital and acute care segments where heparin sodium remains a critical therapeutic agent.